Bayer has appointed Simon Rosof as the new Head of Asia Pacific for its Pharmaceuticals Division, according to an official corporate announcement released on July 28. Based in Singapore, Rosof assumes the role effective July 1, 2026, where he will also direct business strategy and performance across Southeast Asia as the Country Division Head for the Asean cluster.
Leadership Transition in a Dynamic Healthcare Region
Rosof steps into the regional leadership post as the Asia Pacific pharmaceutical market serves a population exceeding 2.6 billion people and features rapidly evolving healthcare systems marked by rising health investments and escalating patient demands for innovative treatments. Sebastian Guth, Chief Operating Officer for Bayer Pharmaceuticals, stated that Rosof’s global commercial experience makes him well-suited to support regional teams in bringing new medicines to patients, praising his track record of delivering growth and developing high-performing teams.
Did you know? The Asia Pacific pharmaceutical landscape spans a population of more than 2.6 billion individuals, making it one of the most dynamic regions for medical innovation and healthcare infrastructure investment globally.
Background and Commercial Expertise Driving Strategy
With more than two decades of experience in the pharmaceutical sector, Rosof brings deep expertise in commercial strategy, portfolio leadership, and market development. Most recently, according to company records, he served as Senior Vice President and Head of Product and Pipeline for Bayer Pharmaceuticals in the United States. In that capacity, he directed commercialization efforts across oncology, cardiovascular and renal, and women’s health care portfolios.
His career history includes significant leadership roles at both Bayer and Bristol Myers Squibb. Notably, Rosof previously served as General Manager for Bristol Myers Squibb Singapore, gaining direct operational experience within the local market. Throughout his career, he has managed portfolios across hematology, virology, metabolic diseases, and oncology.
Strategic Priorities for Bayer in Southeast Asia
Stepping into his dual mandate in Singapore, Rosof highlighted the unique position of the regional healthcare ecosystem. “As demand for innovative treatments continues to grow, we have an opportunity to expand patient access, strengthen partnerships across the health care ecosystem, and help bring meaningful innovations to more people across the region,” Rosof said in a statement.
Prior to entering the pharmaceutical industry, Rosof worked in financial services in New York City with Morgan Stanley and Merrill Lynch. He holds a Bachelor of Arts in Biology from Amherst College and earned an MBA from the Tuck School of Business at Dartmouth.
Pro Tip for Industry Observers
Frequently Asked Questions
When does Simon Rosof assume his new role at Bayer?
Simon Rosof officially assumed his position as Head of Asia Pacific for Bayer’s Pharmaceuticals Division on July 1, 2026.
What are Rosof’s operational responsibilities in Singapore?
In addition to leading the pharmaceuticals division across the Asia Pacific region, Rosof serves as the Country Division Head for the Asean cluster, overseeing business strategy and operational performance throughout Southeast Asia.
What leadership positions did Rosof hold prior to this appointment?
Prior to this role, Rosof served as Senior Vice President and Head of Product and Pipeline for Bayer Pharmaceuticals in the United States and previously held leadership roles, including General Manager for Bristol Myers Squibb Singapore.
What are your thoughts on the evolving pharmaceutical landscape in Asia? Leave a comment below, share this article with your professional network, or subscribe to our newsletter for more industry updates.
Keep reading